Is this email not displaying correctly? View it in your browser.
 
Newswise - News for Journalists
Newswise Special Wire
Tuesday, December 4, 2018

Public edition | newswise.com

Newswise Cancer Research Wire for 04-Dec-2018
 

Cancer Research Wire

Cancer research news for the public and news media. More stories can be found at the Newswise Cancer News Source.



Moffitt Researchers Identify Novel Mechanism to Thwart KRas-driven Tumor Growth

Researchers at Moffitt Cancer Center are trying to devise alternative mechanisms to block KRas. Their recent study demonstrates that the protein GSK3 is an important mediator of KRas-dependent tumor viability. Their research was published today in N...

– Moffitt Cancer Center

Nature Communications, Dec-2018


New Cancer Immunotherapy Approach Turns Human Cells into Tiny Anti-Tumor Drug Factories

In lab and mouse experiments, UC San Diego School of Medicine researchers developed a method to leverage B cells to manufacture and secrete tumor-suppressing microRNAs.

– University of California San Diego Health

Scientific Reports


Research Finds Rivaroxaban Significantly Reduced Blood Clots and Blood Clot-Related Death in Cancer Patients

Cleveland Clinic medical oncologist and researcher, Alok Khorana, M.D., is the primary investigator on a study that concluded rivaroxaban for venous thromboembolism (VTE), a blood clot in the venous system, significantly reduced VTE and VTE-related d...

– Cleveland Clinic


Combination Immunotherapy Shows High Activity Against Recurrent Hodgkin Lymphoma

A new combination of three drugs that harness the body’s immune system is safe and effective, destroying most cancer cells in 95 percent of patients with recurrent Hodgkin lymphoma, according to the results of an early-phase study.

– NYU Langone Health

ASH Annual Meeting, December 2018; R01 CA180820; R01 CA180794; R01 CA180790; R01 CA180795; U10 CA180799; R01 CA180802; R01 CA180816; R01 CA180833...

Embargo expired on 03-Dec-2018 at 13:30 ET


Dana-Farber Scientists to Present New Research on Improving Outcomes in Stem Cell Transplantation for Myeloid Cancers

Improving outcomes for patients with myeloid cancers who undergo stem cell transplantation is a focus of several studies to be presented by Dana-Farber Cancer Institute scientists at the ASH Annual Meeting.

– Dana-Farber Cancer Institute

Embargo expired on 03-Dec-2018 at 18:30 ET


Dana-Farber Scientists to Present Research on Myeloma Progression From Precursor Conditions and Novel Approaches to Treatment

Dana-Farber Cancer Institute scientists will present research marking significant advances against the hematologic cancer multiple myeloma at the ASH Annual Meeting.

– Dana-Farber Cancer Institute

American Society of Hematology (ASH) Annual Meeting

Embargo expired on 03-Dec-2018 at 19:00 ET


Identification of new lymphoma sub-group by Terry Fox Research Institute-funded cancer researchers opens door for potential new treatments for hard-to-treat cancer

The discovery by BC researchers of a group of bad actors ‘hidden’ within a cohort of good ones may translate into new hope for cancer patients diagnosed with a type of lymphoma that doesn’t respond well to treatment.

– Terry Fox Research Institute

Journal of Clinical Oncology (JCO)

Embargo expired on 03-Dec-2018 at 13:00 ET


Researchers Develop Accurate, Non-Invasive Method to Detect Bladder Cancer

A research team has developed a non-invasive method for detecting bladder cancer that might make screening easier and more accurate than current invasive clinical tests involving visual inspection of bladder. In the first successful use of atomic for...

– Tufts University

Proceedings of the National Academy of Science (PNAS) Dec-2018; NSF 1435655

Embargo expired on 03-Dec-2018 at 15:00 ET


Mayo Clinic researchers identify new strategies that may improve CAR-T cell therapy

SAN DIEGO — Mayo Clinic researchers have developed two new strategies that may improve the performance of chimeric antigen receptor therapy (CAR-T cell therapy) in treating cancer. They are presenting results of their preclinical research at the 20...

– Mayo Clinic

Blood; American Society of Hematology (ASH) Annual Meeting

Embargo expired on 03-Dec-2018 at 19:30 ET


New Study Reveals Gut Microbes May Help Protect People Having a Bone Marrow Transplant

Researchers at Memorial Sloan Kettering Cancer Center (MSK) reported results from a new study that looks at the likelihood of complications for people undergoing bone marrow transplants (BMTs). The observational study found that people with lower gut...

– Memorial Sloan Kettering Cancer Center

American Society of Hematology (ASH) 2018 Annual Meeting


Experts in immunotherapy, medical physics and cervical cancer named 2018 ASTRO Gold Medalists

The American Society for Radiation Oncology (ASTRO) recently named three leaders in radiation oncology as the recipients of its Gold Medal award. Patricia Eifel, MD, FASTRO, David Jaffray, PhD, and Ralph Weichselbaum, MD, were awarded the highest hon...

– American Society for Radiation Oncology (ASTRO)

ASTRO’s 60th Annual Meeting


Mayo Researchers Say Oral Apixaban Safe and Effective for Treating Blood Clots in Cancer Patients

SAN DIEGO — Mayo Clinic researchers have found that an oral drug, apixaban, used to treat blood clots in patients undergoing cancer therapy, is safe and effective. The drug was associated with fewer major bleeding events and fewer recurrent blood c...

– Mayo Clinic

American Society of Hematology (ASH) Annual Meeting


New tumor model helps researchers treat pancreatic cancer

Patients diagnosed with pancreatic cancer face a poor prognosis because the tumor forms dense scar-like tissue that is difficult for chemotherapy drugs to penetrate, but a new model may help researchers develop new therapies.

– South Dakota State University

Translational Oncology, 2018


Early results show promise for using genetically engineered immune cells to fight relapsed blood cancer

At the 60th Annual American Society of Hematology Annual Meeting in San Diego on Monday, UNC Lineberger researchers revealed preliminary results from a clinical study of an investigational cellular immunotherapy for Hodgkin lymphoma and non-Hodgkin l...

– University of North Carolina Health Care System

60th Annual ASH Annual Meeting & Exposition


Targeting tumors with 3D animation

Oregon State University engineers are using 3D animations techniques to increase the precision of radiation therapy for prostate cancer so that neighboring healthy tissues and organs are not affected.

– Oregon State University, College of Engineering


National Rheumatology and Psoriasis Organizations Release Joint Guideline for Treating Psoriatic Arthritis

The American College of Rheumatology (ACR) and National Psoriasis Foundation (NPF) have released a joint treatment guideline for psoriatic arthritis (PsA) that provides evidence-based pharmacologic and non-pharmacologic recommendations on caring for ...

– American College of Rheumatology (ACR)

ACR Psoriatic Arthritis Guideline


More than half of patients alive two years after receiving CAR-T therapy for diffuse large B-cell lymphoma in ZUMA-1 trial

A follow-up analysis of patients enrolled in a Phase I/II multi-center trial for diffuse large B-cell lymphoma (DLBCL) reported 51 percent of patients receiving an anti-CD19 chimeric antigen receptor (CAR T) called axi-cel were still alive two years ...

– University of Texas M. D. Anderson Cancer Center

The Lancet Oncology; 60th American Society of Hematology Annual Meeting & Exposition

Embargo expired on 02-Dec-2018 at 12:00 ET


Dana-Farber Researchers Report Clinical Trial Results in Treatment of Leukemia and Lymphoma

New results from clinical trials of immunotherapy and experimental targeted agents for patients with leukemia and lymphoma are being presented by Dana-Farber Cancer Institute researchers at the ASH Annual Meeting.

– Dana-Farber Cancer Institute

American Society of Hematology (ASH) Annual Meeting

Embargo expired on 02-Dec-2018 at 12:30 ET


New Two-year Data Show 39 Percent of Non-Hodgkin Lymphoma Patients Treated with CAR T-cell Therapy Remain in Remission

A new article published today in The Lancet Oncology shows 39 percent of large B cell lymphoma patients treated with the chimeric antigen receptor T-cell therapy (CAR T) Yescarta® (axicabtagene ciloleucel) remained in remission more than two years (...

– Moffitt Cancer Center

The Lancet Oncology, Dec-2018


Studies Suggest that Immunotherapy Adds Punch to Earlier Attempts to Treat Recurrent Non-Hodgkin and Hodgkin Lymphoma

New drugs that harness the body’s immune system to destroy cancer cells appear to increase the effectiveness of later drug therapies for non-Hodgkin and Hodgkin lymphoma patients, new research suggests. This happens, scientists say, even for repeat...

– NYU Langone Health

ASH Annual Meeting, December 2018; R01 CA180820; R01 CA180794; R01 CA180790; R01 CA180795; U10 CA180799; R01 CA180802; R01 CA180816; R01 CA180833...

Embargo expired on 01-Dec-2018 at 21:15 ET


Calcium Signaling May Play Role in Addressing Drug Resistance to Non-Hodgkin Lymphoma Treatment

Systems biology analyses by Rutgers Cancer Institute of New Jersey researchers examining drug resistance to a common antibody therapy for non-Hodgkin lymphoma suggest calcium signaling may have an influence in addressing this treatment obstacle.

– Rutgers Cancer Institute of New Jersey

American Society of Hematology Annual Meeting, Dec-2018

Embargo expired on 01-Dec-2018 at 12:00 ET


Exploring Clinical Activity of an Immunotherapy Drug that Targets Lymphomas

An investigational immunotherapy drug has demonstrated efficacy and an acceptable safety profile in the treatment of follicular lymphoma, diffuse large B-cell lymphoma and other B cell non-Hodgkin lymphoma subtypes. The lead investigator from Rutgers...

– Rutgers Cancer Institute of New Jersey

American Society of Hematology Annual Meeting, Dec-2018

Embargo expired on 01-Dec-2018 at 12:00 ET


Global Trial Shows CAR T Therapy Can Lead to Durable Remissions in Non-Hodgkin’s Lymphoma

In an update to a global clinical trial stretching from Philadelphia to four continents, the chimeric antigen receptor (CAR) T cell therapy Kymriah® (tisagenlecleucel, formerly CTL019) led to long-lasting remissions in patients with relapsed/refract...

– Perelman School of Medicine at the University of Pennsylvania

New England Journal of Medicine

Embargo expired on 01-Dec-2018 at 12:00 ET


CAR-T cell update: therapy improves outcomes for patients with B-cell lymphoma

An international phase-2 trial of a CAR-T cell therapy—to be published on-line Dec. 1 in the New England Journal of Medicine (and presented at the ASH annual meeting in San Diego)—found that 52% of patients responded favorably to the therapy; 40%...

– University of Chicago Medical Center

ASH annual meeting, New England Journal of Medicine

Embargo expired on 01-Dec-2018 at 12:00 ET


New Study Highlights CAR T-cell Therapy Success for Lymphoma When Used as Standard of Care

Moffitt Cancer Center partnered with 16 academic cancer centers to analyze real world data of 274 patients treated commercially with Yescarta® (axicabtagene ciloleucel), one of two CAR T products that is now standard of care for patients with diffus...

– Moffitt Cancer Center

ASH Annual Meeting, Dec-2018


App Helps Breast Cancer Survivors Improve Health After Treatment

Breast cancer survivors who used a smartphone app created at Houston Methodist consistently lost weight, largely due to daily, real-time interactions with their health care team via the mobile app.

– Houston Methodist

JCO CCI, Nov. 30, 2018

Embargo expired on 30-Nov-2018 at 16:00 ET


Immunotherapy Better than Chemotherapy for Subtype of Head and Neck Cancer

A randomized clinical trial involving 97 medical centers in 20 countries, including Moores Cancer Center at UC San Diego Health, found that treating patients with head and neck cancer with the immunotherapy drug pembrolizumab is more effective and le...

– University of California San Diego Health

The Lancet

Embargo expired on 30-Nov-2018 at 18:30 ET


St. Jude research into leukemia, sickle cell and other blood disorders presented at ASH

The 60th Annual Meeting of the American Society of Hematology will feature research from St. Jude Children’s Research Hospital on topics ranging from the genomic basis and vulnerabilities of leukemia to an update on gene therapy for hemophilia B to...

– St. Jude Children's Research Hospital

The 60th Annual Meeting of the American Society of Hematology


Experts Present New Recommendations on 'Overlapping' Type of Leukemia

Chronic myelomonocytic leukemia (CMML) is a rare disease with overlapping features of two categories of bone marrow and blood cell disorders that poses challenges in clinical management. Joint recommendations on diagnosis and treatment of CMML from t...

– Wolters Kluwer Health: Lippincott Williams and Wilkins

Hemasphere


A cancer drug may help treat human papillomavirus infections

Preclinical experiments by University of Alabama at Birmingham researchers suggest the cancer drugs vorinostat, belinostat and panobinostat might be repurposed to treat infections caused by human papillomaviruses, or HPVs.

– University of Alabama at Birmingham

Proceedings of the National Academy of Sciences; CA83679


Venetoclax Combination Approved for Elderly AML

A new option – a combination of a standard drug and the novel agent venetoclax – has been granted accelerated approval by the Food and Drug Administration for certain AML patients after a large, multicenter phase 1 clinical trial showed the combi...

– Dana-Farber Cancer Institute

Blood,Oct-2018


Age Alone Doesn't Increase Complications of Free-Flap Breast Reconstruction in Older Women

Breast reconstruction using a "free flap" from the patient's abdomen is a safe procedure with a high success rate in older women opting for reconstruction after mastectomy, reports a study in the December issue of Plastic and Reconstructive Surgery®...

– Wolters Kluwer Health: Lippincott Williams and Wilkins

Plastic and Reconstructive Surgery


“A 4 percent chance is nothing to me”

Former MLB player Frank Baker says his experience at UAB’s Pancreatobiliary Disease Center was a home run.

– University of Alabama at Birmingham


UT Southwestern Leads the Way in Single-Incision Surgery

UT Southwestern Medical Center this week became the first hospital in Texas to perform single-incision, robotic surgery.

– UT Southwestern Medical Center


WVU Cancer Institute studies new treatment for colorectal cancer using novel drug combination

Richard Goldberg, who directs the West Virginia University Cancer Institute, is searching for new ways to slow colorectal cancer’s progression. In a recent study, he and an international team of scientists investigated a new drug combination for tr...

– West Virginia University

Cancer


At-Home HPV Tests Could Be Powerful Tool for Hard-to-Reach U.S. Women

A new study from The Ohio State University found that mailing at-home HPV tests to hard-to-reach women may be a viable approach, one that could be especially helpful in regions such as Appalachia, where access to women’s health care can be limited....

– Ohio State University

Sexually Transmitted Diseases


New Report Charts Dramatic Growth in the Global Clinical Trial Landscape for PD-1/L1 Immune Checkpoint Inhibitors

Latest Cancer Research Institute update on the landscape of anti-PD1/L1 checkpoint inhibitor clinical trials

– Cancer Research Institute

Tang J. et al. The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. Nat Rev Drug Disc. 17, pp 854-855 (2018)


Brain Cancer Immunotherapy SurVaxM Extends Survival, Even in Hard-to-Treat Patients

The latest results from an ongoing clinical study incorporating the immunotherapy SurVaxM as part of combination treatment for glioblastoma show that this investigational drug is safe, well-tolerated and extended survival even among the hardest-to-tr...

– Roswell Park Comprehensive Cancer Center

SNO 2018 Annual Meeting


Easy to use 3D bioprinting technique creates lifelike tissues from natural materials

Bioengineers have developed a 3D bioprinting technique that works with natural materials and is easy to use, allowing researchers of varying levels of technical expertise to create lifelike tissues, such as blood vessels and a vascularized gut. The g...

– University of California San Diego

Advanced Healthcare Materials, Oct-2018; 1013926; 5-FY15-450; SKF-16-150; 1463689; RO1GM123313; R01HG009285; RO1CA222826; R21CA217735; R01CA206880...


Single cell sequencing sheds light on why cancers form in specific cell types

While many cells in our bodies can accumulate oncogenic mutations, the majority of these events do not lead to tumor formation as these abnormal cells are eliminated by defense mechanisms. Instead, tumors arise when a mutation happens in a particular...

– University of Illinois at Chicago

Nature Communications


FDA Approves New Targeted Drug for Leukemia Tested at University of Pennsylvania

The U.S. Food and Drug Administration (FDA) has approved the first ever inhibitor drug specifically approved for treating patients with relapsed or refractory acute myeloid leukemia (AML) with a mutation in the Fms-like tyrosine kinase 3 (FLT3) gene....

– Perelman School of Medicine at the University of Pennsylvania

The Lancet Oncology


UCLA research suggests widely used breast cancer therapy doesn’t cause cognitive decline

UCLA researchers have found that commonly used hormone therapies for women diagnosed with breast cancer do not appear to cause significant cognitive dysfunction following the treatment.

– University of California, Los Angeles (UCLA), Health Sciences

Cancer


Synthetic Cells Command New Powers of Communication

Researchers at UC San Diego used materials like clay and plastic to create synthetic cells—or “cell-mimics”—capable of gene expression and communication rivaling that of living cells. According to some scientists, these newly published resear...

– University of California San Diego

Nature Communications


The future of fighting cancer: zapping tumors in less than a second

New accelerator-based technology being developed by the Department of Energy’s SLAC National Accelerator Laboratory and Stanford University aims to reduce the side effects of cancer radiation therapy by shrinking its duration from minutes to under ...

– SLAC National Accelerator Laboratory


High-Tech Surgical Suites Let Doctors Scan Patients without Either Leaving the Operating Room

Inside Jacobs Medical Center at UC San Diego Health resides the only intra-operative magnetic resonance imaging surgical suites in Southern California — a high-tech hybrid that gives surgeons access to advanced MRI technology during procedures.

– University of California San Diego Health


Advanced cancer patients can live longer with palliative care, Tulane study says

Researchers sampled more than 2,000 patients with advanced cancers to examine the impact of outpatient palliative care on patients’ survival and quality of life.

– Tulane University

Annals of Behavioral Science, Nov-2018


Announcements


NCCN Oncology Research Program Awarded $2 Million from Lilly to Study Mechanisms of Resistance to CDK4 & 6 Inhibitors in Breast Cancer Treatment

NCCN Oncology Research Program Awarded $2 Million from Lilly to Study Mechanisms of Resistance to CDK4 & 6 Inhibitors in Breast Cancer Treatment

– National Comprehensive Cancer Network® (NCCN®)


UC San Diego Health is First in San Diego to offer CAR T-cell Therapy for Some Cancers

Following the Food and Drug Administration’s approval of chimeric antigen receptor (CAR) T-cell therapies for the treatment of certain types of non-Hodgkin lymphomas, UC San Diego Health was the first medical center in San Diego to be certified to ...

– University of California San Diego Health


MDCalc Launches Beta GI Guideline Summaries with American College of Gastroenterology

NEW YORK, NY — December 3, 2018 — MDCalc, the global leader in online evidence-based medical calculators, has launched its new guideline summaries in a public beta. The first set of 11 summaries debuted at the annual scientific meeting of the Ame...

– American College of Gastroenterology (ACG)


PhRMA Foundation Releases Highlights of its 2018 Funding Efforts

The PhRMA Foundation awarded more than $6 million over the last two years to more than 100 leaders in scientific research in the United States. The Foundation is proud to announce another successful year supporting innovative research efforts in are...

– PhRMA Foundation


Prevention and Screening Clinic at UC San Diego Health Helping to Reduce Pancreatic Cancer

Moores Cancer Center at UC San Diego Health launched the Pancreatic Cancer Prevention and Screening Clinic in an attempt to reduce the number of people who develop the disease and improve survival for those who do. Every day in the U.S., 145 people a...

– University of California San Diego Health


Memorial Sloan Kettering Researchers at ASH Annual Meeting

MSK experts in CAR-T therapy, immunotherapy, leukemia, lymphoma, blood and marrow stem cell transplantation, and more, are also available to comment on meeting news.

– Memorial Sloan Kettering Cancer Center


$2M Grant Expands Social Media Intervention to Reduce Skin Cancer Burden

A $2 million grant from the National Cancer Institute will support the expansion of Rutgers Cancer Institute of New Jersey research focused on sun protective behaviors among young melanoma survivors -- an intervention delivered through social media....

– Rutgers Cancer Institute of New Jersey

R01CA221854-01A1


Lozano named winner of 2018 E.E. Just Award

The 2018 recipient of the E.E. Just Award is Guillermina (Gigi) Lozano, professor and chair of the Department of Genetics, Division of Basic Science Research at the University of Texas MD Anderson Cancer Center in Houston. Lozano will present the E.E...

– American Society for Cell Biology (ASCB)

ASCB|EMBO Meeting


ASRA’s Chronic Pain Medicine Grant Will Evaluate Spinal Cord Stimulation in the Treatment of Cancer Pain

ASRA has awarded the 2018 Chronic Pain Medicine Research Grant to Eellan Sivanesan, MD, for a project looking at the effectiveness of spinal cord stimulation (SCS) for the treatment of chemotherapy-induced painful neuropathy (CIPN). Sivanesan is an a...

– American Society of Regional Anesthesia and Pain Medicine (ASRA)

Tips

CUSTOMIZE YOUR FAVORITES WITH "MY READING LIST"

MY CHANNELS  |  SAVED ARTICLES  |  MY SOURCES  |  MY EXPERTS

MORE CHANNELS:
JOURNAL NEWS   |  TRENDS AND TOP STORIES   |  LOCAL NEWS  |  MEDICAL and SCIENTIFIC MEETINGS

Support
 Subscribe/Unsubscribe
 Edit My Preferences
 Comments/Suggestions
 Contact Us
 
Services
 Newswise Home
 Newswise Contact Directory
 Expert Queries
 Presspass Application

More News from:

 West Virginia University

 SLAC National Accelerator Laboratory

 University of California San Diego Health

 University of California, Los Angeles (UCLA), Health Sciences

 Wolters Kluwer Health: Lippincott Williams and Wilkins

 University of Alabama at Birmingham

 UT Southwestern Medical Center

 Duke Health

 University of Texas M. D. Anderson Cancer Center

 Oregon State University, College of Engineering


Subscribe / Unsubscribe
Edit my preferences

© 2018 Newswise, Inc. All Rights Reserved.

215 E. 5th St. SW, Charlottesville VA 22903 | 434-296-9417

 Contact Us